摘要
观察重组人血管内皮抑制素对人胃癌细胞株SGC-7901表达VEGF的抑制作用,并探讨其可能的作用机制。免疫组化法从蛋白水平检测人胃癌细胞株SGC-7901对VEGF的表达;重组人血管内皮抑制素(恩度)处理SGC-7901后,MTT法检测细胞增殖活性,应用RT-PCR和Western blotting法分别从mRNA和蛋白水平检测VEGF表达量的变化。正常SGC-7901细胞中高表达VEGF,经恩度处理后的SGC-7901细胞增殖情况正常,但VEGF的表达量与用药前相比明显减低。结论:恩度能抑制SGC-7901细胞中VEGF的表达。
The effects of endostatin on the proliferation of human stomach carcinoma cell-line SGC- 7901 and the expression of VEGF were doserved in our experiment. The expression of vascular endothelial growth factor（VEGF） in SGC- 7901 cells was examined by immunocytochemical staining. The proliferation of SGC- 7901 cells was analyzed by MTT assay after treatment with Endostatin, the expression of VEGF was examined by RT-PCR and Western blotting. VEGF were expressed in human SGC- 7901 cells. Endostatin did not inhibit the proliferation of SGC- 7901 cells when the concentrations of endsta- tin were 0.1, 1, 10, and 20 btg/mL, respectively. Expression of VEGF in the SGC- 7901 cells was inhibited by endostatin. Endostatin can not inhibit the proliferation of SGC- 7901 cells but can decrease the expression of VEGF.
出处
《药物生物技术》
CAS
CSCD
2010年第4期308-311,共4页
Pharmaceutical Biotechnology
